{"id":"NCT01945775","sponsor":"Pfizer","briefTitle":"A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)","officialTitle":"A PHASE 3, OPEN-LABEL, RANDOMIZED PARALLEL,2-ARM,MULTI-CENTER STUDY OF TALAZOPARIB(BMN 673) VERSUS PHYSICIAN'S CHOICE IN GERMLINE BRCA MUTATION SUBJECTS WITH LOCALLY ADVANCED AND/OR METASTATIC BREAST CANCER, WHO HAVE RECEIVED PRIOR CHEMOTHERAPY REGIMENS FOR METASTATIC DISEASE","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-10-14","primaryCompletion":"2017-09-15","completion":"2021-03-05","firstPosted":"2013-09-19","resultsPosted":"2018-10-03","lastUpdate":"2022-01-20"},"enrollment":431,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Breast Neoplasms","BRCA 1 Gene Mutation","BRCA 2 Gene Mutation"],"interventions":[{"type":"DRUG","name":"talazoparib","otherNames":[]},{"type":"DRUG","name":"Physician's-Choice","otherNames":[]}],"arms":[{"label":"talazoparib","type":"EXPERIMENTAL"},{"label":"Physician's-Choice","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this open-label, 2:1 randomized phase III trial is to compare the safety and efficacy of talazoparib (also known as BMN 673) versus protocol-specific physician's choice in patients who have locally advanced and/or metastatic breast cancer with germline BRCA mutations.","primaryOutcome":{"measure":"Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment","timeFrame":"Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)","effectByArm":[{"arm":"Talazoparib","deltaMin":8.6,"sd":null},{"arm":"Physician's Choice Treatment","deltaMin":5.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":14},"locations":{"siteCount":362,"countries":["United States","Australia","Belgium","Brazil","France","Germany","Ireland","Israel","Italy","Poland","Russia","South Korea","Spain","Taiwan","Ukraine","United Kingdom"]},"refs":{"pmids":["35091441","30124753","30110579"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":103,"n":286},"commonTop":["Nausea","Fatigue","Anaemia","Headache","Neutropenia"]}}